LAB Q2 2025 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q2 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$22M-3.2% YoY

Gross Profit

$11M48.8% margin

Operating Income

-$26M-118.1% margin

Net Income

-$33M-153.7% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-46.7%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$557M

Total Liabilities

$132M

Stockholders' Equity

$425M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$22M	-3.2%
Gross Profit	$11M	$10M	+2.4%
Operating Income	-$26M	-$30M	+15.1%
Net Income	-$33M	-$46M	+26.8%

Revenue Segments

Product

$16M42%

Consumables

$10M28%

Service and Other Revenue

$6M16%

Instruments

$5M14%

Geographic Segments

EMEA

$9M42%

Americas

$9M40%

Asia Pacific

$4M18%